Compare Cassava Sciences Inc (FLNA) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Taskus Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Taskus Inc trades at $6.02 (market cap $547.18M). The key difference: Taskus Inc is far larger — about 10.3× Cassava Sciences Inc's market cap, and Taskus Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TASK | |
|---|---|---|
Market Cap | $53.14M | $547.18M |
Sector | Health | Technology |
52-Week High | $4.64 | $18.21 |
52-Week Low | $1.09 | $4.57 |
Enterprise Value | -$33.43M | $942.88M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TaskUs (TASK) trades at $6.12, up 5.52% over 24 hours, with a bullish technical signal from moving averages. The company reported strong 2025 results with revenue of $1.18B and net income of $102.28M, supported by a recent CFO appointment and positive robotaxi survey. Valuation ratios like P/E of 5.29 and P/S of 0.46 suggest potential undervaluation relative to earnings and sales.
The outlook is positive with a consensus price target of $9.50, implying significant upside. Risks include Q1 2026 earnings miss and projected negative cash flow for 2026. Analyst sentiment is bullish (55% buy ratings), but investors should monitor execution on future earnings and cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
